FDA Approves RSV Shot Despite High Infant Risk - AI Podcast
Story at-a-glance
- Merck's respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
- Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
- The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
- Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
- Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children
You May Also Like
The Overwhelmed Brain
Paul Colaianni: Relationship and Emotional Abuse Expert
Overthinking Rehab
Motivation
The Resilient Man | Daily Stoic Affirmations
Motivation
Mindset Reset | Daily Motivation
Motivation
Speak with Power | Daily Confidence Boost
Motivation
Healing Affirmations
Motivation
Mood Boosting Workout Affirmations
Motivation
Mental Gym Daily | Train Your Toughness
Motivation
Productivity Mindset Mornings | Daily Affirmations
Motivation
Masculine Mindset | Affirmations for Men
Motivation
The Overwhelmed Brain
Paul Colaianni: Relationship and Emotional Abuse Expert
Overthinking Rehab
Motivation
The Resilient Man | Daily Stoic Affirmations
Motivation
Mindset Reset | Daily Motivation
Motivation
Speak with Power | Daily Confidence Boost
Motivation
Healing Affirmations
Motivation
Mood Boosting Workout Affirmations
Motivation
Mental Gym Daily | Train Your Toughness
Motivation
Productivity Mindset Mornings | Daily Affirmations
Motivation
Masculine Mindset | Affirmations for Men
Motivation
Community discussion